[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-365762-105":59,"doc-detail-365762-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","research-progress-of-sintilimab-in-the-treatment-of-cancer-review","Research progress of sintilimab in the treatment of cancer - (Review)","","Sintilimab is a fully human IgG4 monoclonal antibody targeting the PD-1 pathway and has become an important option in cancer immunotherapy. This review compiles current clinical evidence on its use across non-small cell lung cancer, liver cancer, gastric cancer and neuroendocrine tumors. It examines mechanism of action, structure, pharmacokinetic properties and safety, including immune-related adverse events, and discusses clinical trial outcomes with monotherapy or combinations that improve PFS and OS. It also considers accessibility and future strategies driven by biomarker-based personalized therapy.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/research-progress-of-sintilimab-in-the-treatment-of-cancer-review/365762/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/research-progress-of-sintilimab-in-the-treatment-of-cancer-review/365762.png","ImageObject",300,407,{"name":92,"@type":93},"Jordan Avery","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is sintilimab and what pathway does it target?","Question",{"text":112,"@type":113},"Sintilimab is a fully human IgG4 monoclonal antibody targeting the programmed cell death receptor 1 (PD-1) pathway, acting within the PD-1/PD-L1 axis to support antitumor immune activity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the review describe sintilimab’s effectiveness across cancers?",{"text":117,"@type":113},"The review summarizes clinical data showing antitumor effects in multiple malignancies, including non-small cell lung cancer, liver cancer, gastric cancer and neuroendocrine tumors, when used as monotherapy or in combination regimens.",{"name":119,"@type":110,"acceptedAnswer":120},"What aspects of safety does the review focus on?",{"text":121,"@type":113},"The review analyzes safety with emphasis on immune-related adverse events, and it links sintilimab’s fully humanized nature and high PD-1 binding affinity to a favorable safety profile.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},365762,1790814748,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","ONCOLOGY LETTERS 29: 240, 2025  \nResearch progress of sintilimab in the treatment of cancer  \n(Review)  \nYUAN‑YUAN WU and HUA SHAO  \nDepartment of Pharmacy, Zhongda Hospital of Southeast University, Nanjing, Jiangsu 210009, P.R. China  \nReceived November 8, 2024; Accepted March 5, 2025  \nDOI: 10. 3892/ol.2025.14986  \nAbstract. Sintilimab, a fully human immunoglobulin G4 monoclonal antibody targeting the programmed cell death receptor 1 (PD‑1) pathway, has emerged as significant in cancer immunotherapy, demonstrating promising antitumor effects in various malignancies . The present review summarizes the current clinical data, highlighting the role of sintilimabin treating various types of cancer, including non‑small cell lung cancer, liver cancer, gastric cancer and neuroendocrine tumors. The review also explores the mechanism of action of sintilimab, its structural and pharmacokinetic properties and its safety profile, which includes a comprehensive analysis of immune‑related adverse events. Notably, the high binding affinity of sintilimab to PD‑1 and its fully humanized nature contribute to its potent immunotherapeutic effects and favor‑ able safety profile. Clinical trials have shown that sintilimab, either used as a monotherapy or in combination with chemo‑ therapeutic agents, can significantly extend progression‑free and overall survival in patients with advanced cancers . Furthermore, the economic implications and accessibility of sintilimab, particularly in resource‑limited settings, are discussed. The current review reports on the innovative potential of sintilimab in shaping future cancer treatment strategies and emphasizes the need for personalized therapy based on individual patient biomarkers. The study reveals that sintilimab is not only a viable alternative to existing PD‑1 inhibitors, but also a promising candidate for further research and development in immuno‑oncology.  \nContents  \n1. Introduction  \n2. Introduction to sintilimab  \n3. Specific role of sintilimab in various types of tumors  \nCorrespondence to: Professor Hua Shao, Department of Pharmacy, Zhongda Hospital of Southeast University, 87 Ding Jia Qiao, Nanjing, Jiangsu 210009, P.R. China  \nE‑mail: [13685650553@163.com](13685650553@163.com)  \nKey words: sintilimab, cancer, curative effect, security, progress  \n4. Reflections and prospects  \n5. Conclusions  \n1. Introduction  \nCancer, a prevalent malignant neoplasm in clinical settings, can affect various organs, and is characterized by its rapid progression and high fatality rate, posing a threat to human health. The World Health Organization estimates a 60% rise in global cancer incidence within the next 2 decades, under‑ scoring the severity of prevention and control challenges (1) . The etiology of cancer is rooted in genetic mutations that trigger uncontrolled cell division, followed by factors that exacerbate this growth, enabling cancer cells to penetrate the basement membrane and metastasize to distant organs; this can result in widespread organ failure and ultimately patient mortality (2,3) . The development of cancer is influenced by numerous factors, i.e. external factors, including physical stimuli (such as mechanical stimuli, ultraviolet light, radiation) and biological factors (such as viruses, bacteria); and internal factors, including immune dysfunction, endocrine disordersand genetic factors . All of these factors can increase the risk of cancer by affecting normal cell growth and genetic stability (4,5) .  \nMost types of cancer are initially treated with surgery, which aims to achieve a complete cure. If surgery is not possible, chemotherapy and radiation therapy are used as alternative treatments (6); however, these treatments have poor targeting abilities and can damage normal cells along with cancer cells, leading to serious adverse reactions (7) .  \nRecently, tumor immunotherapy has emerged as a major breakthrough in cancer treatment, which mainly utilizes the human immune system thro","cbCaillPcqruwQuX","https://ap.wps.com/l/cbCaillPcqruwQuX","pdf",1732094,11,"English","# Introduction\n# Introduction to sintilimab\n# Specific role of sintilimab in various types of tumors\n# Reflections and prospects\n# Conclusions","[{\"question\":\"What is sintilimab and what pathway does it target?\",\"answer\":\"Sintilimab is a fully human IgG4 monoclonal antibody targeting the programmed cell death receptor 1 (PD-1) pathway, acting within the PD-1/PD-L1 axis to support antitumor immune activity.\"},{\"question\":\"How does the review describe sintilimab’s effectiveness across cancers?\",\"answer\":\"The review summarizes clinical data showing antitumor effects in multiple malignancies, including non-small cell lung cancer, liver cancer, gastric cancer and neuroendocrine tumors, when used as monotherapy or in combination regimens.\"},{\"question\":\"What aspects of safety does the review focus on?\",\"answer\":\"The review analyzes safety with emphasis on immune-related adverse events, and it links sintilimab’s fully humanized nature and high PD-1 binding affinity to a favorable safety profile.\"}]","Research progress of sintilimab in the treatment of cancer - (Review) | PDF",1790162231,28]